About The Conference

About The Conference Organizers
Expert Speakers
Confirmed Exhibitors
Download Brochure
Promotional Opportunities
Exhibitors & Sponsorship Registration
Delegate Registration Form
Delegates Registration - Online Payment
Past Events

Mr. Leo Mavely
Founder & CEO
Axio Biosolutions Pvt. Ltd.

Leo Mavely is the CEO of Axio Biosolutions a medtech company focused on military medicine and surgical solutions. Axio developed Axiostat – India’s First and only USFDA approved trauma hemostat that stops life threatening bleeding instantly. Axiostat is is being used by soldiers in over 350 battallions across India to manage bleeding from injuries in battlefield. It is approved in over 40 countries and used by major armed forces globally.

A bioengineer by qualification, Leo invented the core technology of Axio and has been instrumental in building Axio soon after college during his tenure at Nirmalabs. Leo holds multiple patents and publications in the field of novel biomaterials for medical tech applications.

Leo was featured in the list of 40 under 40 emerging business leaders by Fortune Magazine consecutively in 2016, 2017, 2018 and 2019 and in the list of 35 under 35 entrepreneurs by Entrepreneur magazine in 2020. Leo was honored as Çhampions of Change by Prime minister, Sh Narendra Modi in 2017. He was the recipient of Silicon valley challenge 2014, Anjani Mashelkar Inclusive Innovation Award 2013, CNBC Samsung Social Innovation Award 2012 and was invited speaker at Indian Science congress 2010.

Axio Biosolutions Private Limited is medtech startup focused on Military medicine, Surgical solutions and Advanced wound care. Axiostat® its flagship product which was developed by its Founder - Leo Mavely to reduce the mortality due to traumatic bleeding from life threatening injuries. Axiostat® is being widely used by Military, Hospitals, Ambulance services, Industries, Relief aid and is part of standard field kit of defence forces in India. Axiostat has been instrumental in helping save lives of soldiers during surgical strike – 2016 and also continue to support humanitarian missions during recent European conflicts.

Axiostat® has also received the prestigious European CE approval, USFDA approval and is being exported to 40+ countries. It was recently launched in hospitals in United States and is the first Indian medical device – hemostat to do so. Axio has raised over $20mn USD in venture funding from Accel Partners, Ratan Tata’s UC-RNT Fund, Omidyar network, Chiratate venture and TrueScale capital. Axio has its state of the art R&D and manufacturing facility at Ahmedabad, Gujarat and Corporate office at Bengaluru, India.